Breast Cancer Treatment Decreases Serum Levels of TGF-β1, VEGFR2, and TIMP-2 Compared to Healthy Volunteers: Significance for Therapeutic Outcomes?
Various complications from a breast cancer treatment, in the pathogenesis of which excessive tissue fibrosis plays a leading role, are a common pathology. In this study, the levels of TGF-β1, VEGFR-2, and TIMP-2 were determined by the immuno-enzyme serum analysis for patients during the long-term pe...
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-09-01
|
| Series: | Pathophysiology |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1873-149X/29/3/42 |
| _version_ | 1827657982899388416 |
|---|---|
| author | Varvara Krasnikova Maria Pospelova Olga Fionik Tatyana Alekseeva Konstantin Samochernykh Nataliya Ivanova Nikita Trofimov Tatyana Vavilova Elena Vasilieva Albina Makhanova Samwel Tonyan Alexandra Nikolaeva Evgeniya Kayumova Maxim Shevtsov |
| author_facet | Varvara Krasnikova Maria Pospelova Olga Fionik Tatyana Alekseeva Konstantin Samochernykh Nataliya Ivanova Nikita Trofimov Tatyana Vavilova Elena Vasilieva Albina Makhanova Samwel Tonyan Alexandra Nikolaeva Evgeniya Kayumova Maxim Shevtsov |
| author_sort | Varvara Krasnikova |
| collection | DOAJ |
| description | Various complications from a breast cancer treatment, in the pathogenesis of which excessive tissue fibrosis plays a leading role, are a common pathology. In this study, the levels of TGF-β1, VEGFR-2, and TIMP-2 were determined by the immuno-enzyme serum analysis for patients during the long-term period after breast cancer treatment as potential markers of fibrosis. The single-center study enrolled 92 participants, which were divided into two age-matched groups: (1) 67 patients following breast cancer treatment, and (2) 25 healthy female volunteers. The intergroup analysis demonstrated that the patients after breast cancer treatment showed a decrease in the serum levels of TGF-β1 (U = 666, <i>p </i>< 0.001) and TIMP-2 (U = 637, <i>p </i>< 0.001) as compared to the group of healthy volunteers. The levels of VEGFR-2 in these groups were comparable (U = 1345, <i>p </i>= 0.082). It was also found that the type of treatment, the presence of lymphedema, shoulder joint contracture, and changes in lymphoscintigraphy did not affect the levels of TGF-β1, VEGFR-2, and TIMP-2 within the group of patients after breast cancer treatment. These results may indicate that these biomarkers do not play a leading role in the maintenance and progression of fibrosis in the long-term period after breast cancer treatment. The reduced levels of TGF-β1 and TIMP-2 may reflect endothelial dysfunction caused by the antitumor therapy. |
| first_indexed | 2024-03-09T22:52:32Z |
| format | Article |
| id | doaj.art-b2d1de7165f948fa952ab461daa411f6 |
| institution | Directory Open Access Journal |
| issn | 1873-149X |
| language | English |
| last_indexed | 2024-03-09T22:52:32Z |
| publishDate | 2022-09-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Pathophysiology |
| spelling | doaj.art-b2d1de7165f948fa952ab461daa411f62023-11-23T18:17:12ZengMDPI AGPathophysiology1873-149X2022-09-0129353755410.3390/pathophysiology29030042Breast Cancer Treatment Decreases Serum Levels of TGF-β1, VEGFR2, and TIMP-2 Compared to Healthy Volunteers: Significance for Therapeutic Outcomes?Varvara Krasnikova0Maria Pospelova1Olga Fionik2Tatyana Alekseeva3Konstantin Samochernykh4Nataliya Ivanova5Nikita Trofimov6Tatyana Vavilova7Elena Vasilieva8Albina Makhanova9Samwel Tonyan10Alexandra Nikolaeva11Evgeniya Kayumova12Maxim Shevtsov13Personalized Medicine Centre, Almazov National Medical Research Centre, 2 Akkuratova Str., 197341 Saint Petersburg, RussiaPersonalized Medicine Centre, Almazov National Medical Research Centre, 2 Akkuratova Str., 197341 Saint Petersburg, RussiaPersonalized Medicine Centre, Almazov National Medical Research Centre, 2 Akkuratova Str., 197341 Saint Petersburg, RussiaPersonalized Medicine Centre, Almazov National Medical Research Centre, 2 Akkuratova Str., 197341 Saint Petersburg, RussiaPersonalized Medicine Centre, Almazov National Medical Research Centre, 2 Akkuratova Str., 197341 Saint Petersburg, RussiaPersonalized Medicine Centre, Almazov National Medical Research Centre, 2 Akkuratova Str., 197341 Saint Petersburg, RussiaPersonalized Medicine Centre, Almazov National Medical Research Centre, 2 Akkuratova Str., 197341 Saint Petersburg, RussiaPersonalized Medicine Centre, Almazov National Medical Research Centre, 2 Akkuratova Str., 197341 Saint Petersburg, RussiaPersonalized Medicine Centre, Almazov National Medical Research Centre, 2 Akkuratova Str., 197341 Saint Petersburg, RussiaPersonalized Medicine Centre, Almazov National Medical Research Centre, 2 Akkuratova Str., 197341 Saint Petersburg, RussiaPersonalized Medicine Centre, Almazov National Medical Research Centre, 2 Akkuratova Str., 197341 Saint Petersburg, RussiaPersonalized Medicine Centre, Almazov National Medical Research Centre, 2 Akkuratova Str., 197341 Saint Petersburg, RussiaPersonalized Medicine Centre, Almazov National Medical Research Centre, 2 Akkuratova Str., 197341 Saint Petersburg, RussiaPersonalized Medicine Centre, Almazov National Medical Research Centre, 2 Akkuratova Str., 197341 Saint Petersburg, RussiaVarious complications from a breast cancer treatment, in the pathogenesis of which excessive tissue fibrosis plays a leading role, are a common pathology. In this study, the levels of TGF-β1, VEGFR-2, and TIMP-2 were determined by the immuno-enzyme serum analysis for patients during the long-term period after breast cancer treatment as potential markers of fibrosis. The single-center study enrolled 92 participants, which were divided into two age-matched groups: (1) 67 patients following breast cancer treatment, and (2) 25 healthy female volunteers. The intergroup analysis demonstrated that the patients after breast cancer treatment showed a decrease in the serum levels of TGF-β1 (U = 666, <i>p </i>< 0.001) and TIMP-2 (U = 637, <i>p </i>< 0.001) as compared to the group of healthy volunteers. The levels of VEGFR-2 in these groups were comparable (U = 1345, <i>p </i>= 0.082). It was also found that the type of treatment, the presence of lymphedema, shoulder joint contracture, and changes in lymphoscintigraphy did not affect the levels of TGF-β1, VEGFR-2, and TIMP-2 within the group of patients after breast cancer treatment. These results may indicate that these biomarkers do not play a leading role in the maintenance and progression of fibrosis in the long-term period after breast cancer treatment. The reduced levels of TGF-β1 and TIMP-2 may reflect endothelial dysfunction caused by the antitumor therapy.https://www.mdpi.com/1873-149X/29/3/42breast cancer survivorspost-mastectomy pain syndromebreast cancerfibrosis moleculesTGF-β1VEGFR2 |
| spellingShingle | Varvara Krasnikova Maria Pospelova Olga Fionik Tatyana Alekseeva Konstantin Samochernykh Nataliya Ivanova Nikita Trofimov Tatyana Vavilova Elena Vasilieva Albina Makhanova Samwel Tonyan Alexandra Nikolaeva Evgeniya Kayumova Maxim Shevtsov Breast Cancer Treatment Decreases Serum Levels of TGF-β1, VEGFR2, and TIMP-2 Compared to Healthy Volunteers: Significance for Therapeutic Outcomes? Pathophysiology breast cancer survivors post-mastectomy pain syndrome breast cancer fibrosis molecules TGF-β1 VEGFR2 |
| title | Breast Cancer Treatment Decreases Serum Levels of TGF-β1, VEGFR2, and TIMP-2 Compared to Healthy Volunteers: Significance for Therapeutic Outcomes? |
| title_full | Breast Cancer Treatment Decreases Serum Levels of TGF-β1, VEGFR2, and TIMP-2 Compared to Healthy Volunteers: Significance for Therapeutic Outcomes? |
| title_fullStr | Breast Cancer Treatment Decreases Serum Levels of TGF-β1, VEGFR2, and TIMP-2 Compared to Healthy Volunteers: Significance for Therapeutic Outcomes? |
| title_full_unstemmed | Breast Cancer Treatment Decreases Serum Levels of TGF-β1, VEGFR2, and TIMP-2 Compared to Healthy Volunteers: Significance for Therapeutic Outcomes? |
| title_short | Breast Cancer Treatment Decreases Serum Levels of TGF-β1, VEGFR2, and TIMP-2 Compared to Healthy Volunteers: Significance for Therapeutic Outcomes? |
| title_sort | breast cancer treatment decreases serum levels of tgf β1 vegfr2 and timp 2 compared to healthy volunteers significance for therapeutic outcomes |
| topic | breast cancer survivors post-mastectomy pain syndrome breast cancer fibrosis molecules TGF-β1 VEGFR2 |
| url | https://www.mdpi.com/1873-149X/29/3/42 |
| work_keys_str_mv | AT varvarakrasnikova breastcancertreatmentdecreasesserumlevelsoftgfb1vegfr2andtimp2comparedtohealthyvolunteerssignificancefortherapeuticoutcomes AT mariapospelova breastcancertreatmentdecreasesserumlevelsoftgfb1vegfr2andtimp2comparedtohealthyvolunteerssignificancefortherapeuticoutcomes AT olgafionik breastcancertreatmentdecreasesserumlevelsoftgfb1vegfr2andtimp2comparedtohealthyvolunteerssignificancefortherapeuticoutcomes AT tatyanaalekseeva breastcancertreatmentdecreasesserumlevelsoftgfb1vegfr2andtimp2comparedtohealthyvolunteerssignificancefortherapeuticoutcomes AT konstantinsamochernykh breastcancertreatmentdecreasesserumlevelsoftgfb1vegfr2andtimp2comparedtohealthyvolunteerssignificancefortherapeuticoutcomes AT nataliyaivanova breastcancertreatmentdecreasesserumlevelsoftgfb1vegfr2andtimp2comparedtohealthyvolunteerssignificancefortherapeuticoutcomes AT nikitatrofimov breastcancertreatmentdecreasesserumlevelsoftgfb1vegfr2andtimp2comparedtohealthyvolunteerssignificancefortherapeuticoutcomes AT tatyanavavilova breastcancertreatmentdecreasesserumlevelsoftgfb1vegfr2andtimp2comparedtohealthyvolunteerssignificancefortherapeuticoutcomes AT elenavasilieva breastcancertreatmentdecreasesserumlevelsoftgfb1vegfr2andtimp2comparedtohealthyvolunteerssignificancefortherapeuticoutcomes AT albinamakhanova breastcancertreatmentdecreasesserumlevelsoftgfb1vegfr2andtimp2comparedtohealthyvolunteerssignificancefortherapeuticoutcomes AT samweltonyan breastcancertreatmentdecreasesserumlevelsoftgfb1vegfr2andtimp2comparedtohealthyvolunteerssignificancefortherapeuticoutcomes AT alexandranikolaeva breastcancertreatmentdecreasesserumlevelsoftgfb1vegfr2andtimp2comparedtohealthyvolunteerssignificancefortherapeuticoutcomes AT evgeniyakayumova breastcancertreatmentdecreasesserumlevelsoftgfb1vegfr2andtimp2comparedtohealthyvolunteerssignificancefortherapeuticoutcomes AT maximshevtsov breastcancertreatmentdecreasesserumlevelsoftgfb1vegfr2andtimp2comparedtohealthyvolunteerssignificancefortherapeuticoutcomes |